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A Need for African-Led Health
R&D Innovation
The health status of the African popu-
lation remains behind that of populations
in Europe and North America, as well as
many other developing regions with sim-
ilar affluence (Figure S1). For example,
Africa is especially affected by a series of
infectious diseases that are responsible for
more than half of its disability-adjusted life
years (DALYs) and over 6 million deaths
per year (Figure S2). For the 18 diseases
listed in Figure S2 Africa has over 30%,
and in some cases over 90%, of the
worldwide disease burden, even though it
represents only 15% of the global popula-
tion. Currently, there are limited or no
affordable therapies or vaccines for many
of these conditions, and diagnostic meth-
ods, where they exist, are often inadequate
to deploy in the field for large populations
[1–5]. Accurate quantification of the
economic impact of disease burden is
difficult. However, the negative impact of
these diseases to the African gross domes-
tic product (GDP) may run into tens of
billions of dollars (US) each year [5–7].
Despite some welcome increases in
global R&D investment in recent years
(e.g., through public private partnerships),
it is generally agreed that research and
product pipelines for the diseases that
disproportionately affect developing coun-
tries are grossly inadequate. This has
recently been reinforced by the 192
countries composing the World Health
Assembly through resolutions supporting
GSPOA (the Global Strategy and Plan of
Action on Public Health, Innovation and
Intellectual Property) [8,9]. There is
urgent need for enhanced research in
developing countries. Our analysis suggest
that, in addition to the scant research for
several diseases, only 21% of total bio-
medical research publications and 31% of
clinical trials in Africa are related to
diseases that account for approximately
50% of the African disease burden
(Figure 1).
One of the underlying emphases of the
GSPOA was that a sustainable global
solution requires greater efforts to build
and utilize innovation capabilities in
developing countries, enhance their access
to information and technology, and forge
collaborative networks. Implementing
these goals and a sustainable pan-African
health product R&D endeavor requires
capacity, infrastructure, leadership, financ-
ing, and an understanding of the status of
health R&D in the African continent. In a
related development, the African Union
have committed to raising spending on
scientific research and innovation to 1% of
GDP in recognition that such funding is a
necessary prerequisite for sustainable de-
velopment [10]. We therefore assessed the
African biomedical research landscape
including the level of intra-African exper-
tise and collaboration to support the
development of the African Network for
Drug and Diagnostics Innovation (ANDI)
in contributing to the implementation of
these goals.
Health R&D in Africa: Variable
Capacity and Lack of
Intra-African Collaboration
We mapped the African health research
landscape by building a database of all
peer-reviewed research articles in biomed-
ical fields that had at least one African-
based author, during the 5-year period
2004 to 2008. The methodology for data
collection and analysis is presented in
Figure 2 (additional information is also
provided in Text S1 and Table S3). The
affiliation of authors in a total of 31,279
articles identified were processed to deter-
mine the lead and collaborating institu-
tions in each article. For every institution,
the number of individual collaborations
was quantified and mapped.
We identified about 2,700 institutions in
Africa as lead institutions based on the fact
that they were the corresponding institu-
tions for articles cited in the peer-reviewed
article database. These are present in 47 of
the 53 African countries (excluding Cape
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Tome ´ and Principe, Somalia, and Bur-
undi). This significant number indicates
that quality R&D capacity exists in the
continent. Figure 3 illustrates centres of
expertise with more than 30 biomedical
publications. Concurrently, mapping of
clinical trial activity in Africa also high-
lights the existence of significant capacity,
as well as pharmaceutical manufacturing
capacity with over 120 companies identi-
fied and some patent activity (data not
shown). However, the data also highlight
the challenging reality that distribution of
R&D capacity is uneven in Africa. These
findings are consistent with, but go
beyond, an earlier report on product
R&D landscape in Africa [11,12].
Among the top 20 most productive
institutions, i.e., those with the highest
number of articles published, we found
that only three African countries are
represented (South Africa, Egypt, and
Nigeria). This analysis show that portions
of Western and Central Africa are signif-
icantly lagging behind (Figure 3). This
trend is further confirmed by patent
productivity, which is concentrated in a
few countries in Africa (data not shown).
These patterns underscore the value of
increasing collaboration across African
countries to both increase and leverage
the available expertise to enhance R&D
capacity.
We next assessed the nature of collab-
orative activity by African institutions.
While 77% of articles in our database
are authored in collaboration, only 5.4%
involve institutions in more than one
African country, and fewer than 1%
involve more than two African countries.
The vast majority of collaborations are
with external partners in Europe and the
United States. Even the most collaborative
African institutions have little collabora-
tion with African countries other than
their own (Table S1). This further con-
Summary Points
N A novel approach to supporting health product research and development
(R&D) and access in Africa is urgently needed. Successful implementation of
such an endeavor requires sustainable capacity, infrastructure, funding,
leadership, and an understanding of the status of health R&D in the African
continent.
N As part of the development of the African Network for Drugs and Diagnostics
Innovation (ANDI), we analyzed biomedical research output and collaborative
research undertaken across the continent by evaluating peer-reviewed articles
published between 2004 and 2008, as well as other innovation indicators, such
as R&D investments and manufacturing capacity.
N Significant health R&D capacity exists in different parts of Africa, but this
capacity is fragmented, uncoordinated, and not properly utilized to address
African health problems. Most biomedical collaborations of African institutions
are with institutions in Europe and the United States rather than with other
African institutions. This lack of intracontinental collaboration, combined with
low levels of investment, contributes to gaps in the continental research
agenda, a lack of local ownership of research undertaken on the continent, and
suboptimal utilization of available research capability.
N We discuss the establishment of ANDI as a new approach to address these
challenges, through the creation, coordination, and funding of African health
R&D networks focused on the discovery, development, and delivery of tools to
address Africa’s unique health needs.
Figure 1. Diseases disproportionately affecting Africa are under-prioritized. Only 21% of all articles with at least one African author focus
on the conditions causing highest disease burden in Africa. This reduced research focus mirrors the low number of products being tested in clinical
trials (only ,1/3 of trials). African DALYs were obtained from the Global Burden of Disease project of WHO. Peer-reviewed articles with at least one
African author published in the biomedical fields during the 5-year period between 2004 and 2008 were identified by querying the Thomson Web of
Science database for African countries in the affiliation field (Figure 2 and Text S1). Absolute numbers of clinical trials were identified using the
ClinicalTrials.gov database (as of September 2009). All trials for drugs and biological products with at least one center in Africa were considered and
all 53 focus countries were scanned. Only trials ‘‘currently open’’ or ‘‘recently completed’’ (i.e., concluded within 48 months of scan date) were
counted. A total of 1,627 trials were identified, out of which 511 trials focus on drugs or biologicals for diseases identified as causing the highest
disease burden in Africa (see left column of charts).
doi:10.1371/journal.pmed.1000293.g001
PLoS Medicine | www.plosmedicine.org 2 June 2010 | Volume 7 | Issue 6 | e1000293Figure 2. Flow chart: Creation of Bibliographic databases.
doi:10.1371/journal.pmed.1000293.g002
Figure 3. Distribution of R&D capacity in Africa. Mapping of the top African cities by research output shows hotspots of R&D activity, but also
highlights inequities in R&D productivity across the continent. To create this mapping we used articles with Africa-based authors in the
corresponding address. A total of 20,119 articles were identified (Figure 2 and Text S1), but for simplicity only African cities with over 30 articles from
2004 to 2008 are marked. This represents 16,647 articles (circle diameter indicates number of published articles; a total of 91 cities in 28 countries are
identified but only the top 40 are labeled).
doi:10.1371/journal.pmed.1000293.g003
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collaboration. The focus of collaboration
with the United States and European
countries is illustrated by the R&D
network mapping for two critical diseases
disproportionately affecting Africa: HIV/
AIDS and malaria (Figures 4 and S3).
These figures identify the top 20 city nodes
of collaboration using measures of ‘‘de-
gree’’ and ‘‘betweenness’’ for each disease
and mapping their main collaborative
partners (see Text S1). These measures
are commonly used as measures of net-
work centrality [13–17]. Other diseases
disproportionately affecting Africa show a
similar pattern (Table S2).
A closer look at the HIV/AIDS and
malaria network maps reveals some subtle
differences in relation to these two diseas-
es: (a) there are significantly more research
articles for HIV/AIDS than for malaria,
but the percentage of African collabora-
tion is approximately twice as high for
malaria (13%) as for HIV/AIDS (7%)
(Table S2); (b) malaria collaborations are
more widely spread across Africa than
they are for HIV/AIDS; (c) HIV/AIDS
research more strongly partners with the
US, while malaria research more strongly
partners with Europe. A clear explanation
for these differences will require more
work. However, we believe that the higher
collaboration seen for malaria is a reflec-
tion of a longer history of local malaria
research in Africa.
Implications of Data for the
Development of African-Led
Health R&D Innovation
While the extra-African collaboration
should be encouraged, the lack of intra-
African collaboration suggests that African
institutions do not have adequate leader-
ship and ownership of the research being
done in the continent. The sustainability
of research undertaken in Africa may also
be an issue, especially when it is under-
taken with short-term funds coming from,
and directed from, external sources. The
poor intra-African collaboration was con-
firmed by interviews in Africa. Over 170
stakeholders were interviewed across Afri-
can countries/regions including ministries
of health, science and technology, and
higher education; national academies of
science; pharmaceutical companies and
research centers; and networks and uni-
versities in South Africa, Nigeria, Egypt,
Kenya, and Burkina Faso [6]. These
interviews identified key factors believed
to hamper collaboration, ownership, and
leadership of research in Africa. These
include the lack of knowledge about R&D
done in other African countries, the
deficient networking infrastructure, and
the absence of financial incentives to spur
cooperative research within the continent.
Increasing R&D activities for under-
researched diseases and promoting collab-
orative networks within Africa will require
robust African-based funding mechanisms
to complement current funding that is
coming mostly from outside Africa. Based
on data from the UNESCO Science
Report 2005, Africa spent 0.3% of GDP
on R&D in 2002, in contrast to a global
value of 1.7%. Increased local funding and
intra-African coordination to complement
external support and coordination are
essential to spur much-needed health
R&D and empower Africa in driving its
own R&D agenda. Overdependence on
external sources alone will continue to
leave a substantial portion of Africa health
needs unaddressed, and will not resolve
the leadership and ownership gap. The
implementation of ANDI is hoped to help
in addressing these challenges.
The African Network for Drugs
and Diagnostics Innovation
The global momentum to increase
participation and leadership of low-in-
come countries in their own R&D pro-
Figure 4. Collaboration bias towards the US and Europe for the HIV/AIDS R&D network. Network mapping of most collaborative
institutions leading articles identified as directly related to HIV/AIDS and published from 2004 to 2008. There are eight top centers in Africa, mostly in
the Southern region. Few articles are published in collaboration between these African centers but there is active collaboration with institutions in
the Northern Hemisphere, mainly in the US. Yellow circles indicate institutions in Africa and red circles mark institutions outside of Africa. Circle
diameter indicates the count of HIV/AIDS articles identified in the analyzed period. Only the top most collaborative institutions in the network and
the links to and from Africa among them are shown. Institutions outside Africa that do not show connections (e.g., Institut Pasteur) are linked to other
institutions outside Africa or to institutions not identified as the most collaborative.
doi:10.1371/journal.pmed.1000293.g004
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World Health Assembly resolutions on
the Global Strategy and Plan of Action on
Public Health, Innovation and Intellectual
Property [8,9]. This guiding framework
calls for improvement in health R&D
innovation through greater engagement
of developing countries, investment in
local capacity and capability building
including support for regional R&D col-
laborative networks, and devising mecha-
nisms to ensure financial sustainability of
local R&D efforts. This is consistent with
other high-level pan-African declarations,
for example the Algiers declaration of
2008 [18]. This is a propitious moment to
address the need for medicines in Africa,
with a pragmatic and sustainable model
that: (a) promotes the assembly of African
R&D networks that can better use the
technology and human capital already
present on the Continent, (b) sustainably
funds R&D projects aligned with African
health priorities and led by African R&D
centers, (c) ensures African ownership of
the R&D agenda, and (d) supports broader
south–south and south–north collabora-
tion and technology transfer.
A strategic business plan to guide the
implementation and financing of drugs
and diagnostics research—ANDI—has
been developed by a series of partners
such as WHO through TDR, AFRO
(WHO African Regional Office), and
EMRO (WHO Eastern Mediterranean
Regional Office), the African Develop-
ment Bank, the European Union, and
several national African institutions [6].
The plan calls for the establishment of an
African innovation fund to support ANDI
activities. Discussions are ongoing to
formally establish an African-led gover-
nance structure for ANDI under the
auspices of an African institution in
2010, and to operationally launch the
initiative with a set of well-defined projects
in 2011.
The business plan’s development in-
volved multiple consultative discussions,
analyses, and over 170 stakeholder inter-
views. The plan calls for a US$600 million
endowment fund in Africa that can
complement other, more classical, dona-
tions to generate a sustainable income of
up to US$30 million annually to support
African health product innovation. ANDI
aims to partner, fund, and coordinate
research by creating a portfolio of collab-
orative project networks and partnerships
as well as building capacity and support
for infrastructural development. It will also
advocate for more investment for research
to be done throughout Africa and support
local intellectual property management
capability for enhanced access to medi-
cines. Recent discussions with various
stakeholders have also emphasized the
need for ANDI to remain open to include
research on a broad range of products,
including drugs, diagnostics, vaccines, and
medical devices. They have also stressed
the need for downstream research to
strengthen and support health systems.
ANDI will complement external R&D
efforts, such as those promoted by product
development partnerships that focus on
one or a few diseases. These include,
Medicines for Malaria Venture (www.
mmv.org), Drugs for Neglected Diseases
Initiative (www.dndi.org), Foundation
for Innovative New Diagnostics (www.
finddiagnostics.org) and Malaria Vaccine
Initiative (www.malariavaccine.org/) [19].
It will also complement and partner other
continental initiatives such as EDCTP
(European and Developing Countries
Clinical Trials Partnership, http://www.
edctp.org/), AMANET (African Malaria
Network Trust, http://www.amanet-trust.
org/), and AAVP (African AIDS Vaccine
Programme, http://www.who.int/vaccine_
research/diseases/hiv/aavp/en/) [20],
which focus primarily on clinical research.
It will also complement capacity-building
efforts such as those of the Wellcome
Trust focusing on academic biomedical
research capacity in specific countries
such as Kenya and Malawi. ANDI covers
the entire innovation value chain from
discovery to manufacture and links both
health and innovation sectors to economic
development.
Funds have been secured, including
from the European Union, to support the
initial establishment of ANDI. However,
further resources are being sought to
operationalise it in Africa. Next steps for
the establishment of ANDI include: (a) the
formal establishment of a governance
structure; (b) the selection of host sites for
the regional and sub-regional offices; (c)
the selection and establishment of an
initial set of projects and technological
support platforms; and (d) recruitment of
staff. It is anticipated that these milestones
will be achieved by 2011. Progress towards
these activities will be reported at the 3rd
ANDI stakeholders’ meetings scheduled
for Nairobi in October 2010.
The establishment of ANDI as a func-
tional and successful organization located
in Africa—managed and governed by
African institutions, implementing product
R&D, and ensuring sustainable access to
new drugs and diagnostics innovations—
will help fill the gaps identified in this work,
including deficient investment in product
R&D within Africa; a lack of collaboration
among African scientists and between the
African public and private sector; and poor
awareness of the link between research and
economic development.
Supporting Information
Figure S1 Life expectancy in Africa.
Life expectancy in Africa is in general
lower than in other areas of the developing
world (e.g., Asia). This is independent of
economic development, as measured by
GDP per capita. GDP per capita is shown
in a logarithmic scale, and correspond to
purchasing power parity (PPP) in 2007. All
measurements obtained from the United
Nations [5].
Found at: doi:10.1371/journal.pmed.
1000293.s001 (0.16 MB TIF)
Figure S2 Disease burden caused by
diseases disproportionally affecting Africa.
Diseases that show high relative impact in
Africa, i.e., cause over 30% of total global
disease burden as measured by DALYs.
DALY is a time-based measure combining
years of life lost to premature mortality
and years of life lost to time lived in states
of less than full health. These are respon-
sible for 54% of all African DALYs and
approximately half of all deaths.
Found at: doi:10.1371/journal.pmed.
1000293.s002 (0.41 MB TIF)
Figure S3 Collaboration bias towards
the US and Europe for the malaria R&D
network. Network mapping of most col-
laborative institutions leading articles iden-
tified as directly related to malaria and
published from 2004 to 2008. There are
nine top centers in Africa spread across the
continent, except in the northern region.
Few articles are published in collaboration
between African centers, but these are
active in collaborating with institutions in
the Northern Hemisphere, mainly in
Europe. Yellow circles indicate institutions
in Africa; red circles mark institutions
outside of Africa. Circle diameter indicates
the count of malaria articles identified in
the analyzed period. Only the top most-
collaborative institutions in the network
and the links to and from Africa among
them are shown.
Found at: doi:10.1371/journal.pmed.
1000293.s003 (0.55 MB TIF)
Table S1 Most-collaborative African
institutions.
Found at: doi:10.1371/journal.pmed.
1000293.s004 (0.41 MB TIF)
Table S2 African R&D output in eight
key disease areas in Africa.
Found at: doi:10.1371/journal.pmed.
1000293.s005 (0.18 MB TIF)
PLoS Medicine | www.plosmedicine.org 5 June 2010 | Volume 7 | Issue 6 | e1000293Table S3 Subject areas excluded to
restrict the dataset to biomedical publica-
tions.
Found at: doi:10.1371/journal.pmed.
1000293.s006 (0.72 MB TIF)
Text S1 Methodology.
Found at: doi:10.1371/journal.pmed.
1000293.s007 (0.03 MB DOC)
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